Spruce Street Capital LP bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 329,006 shares of the company’s stock, valued at approximately $16,697,055,000. Enliven Therapeutics comprises about 3.3% of Spruce Street Capital LP’s portfolio, making the stock its 10th largest holding. Spruce Street Capital LP owned 0.45% of Enliven Therapeutics at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of ELVN. KBC Group NV acquired a new stake in Enliven Therapeutics during the 1st quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP raised its holdings in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
Enliven Therapeutics Stock Up 2.2%
Shares of NASDAQ:ELVN opened at $61.15 on Tuesday. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The firm’s 50-day simple moving average is $53.36 and its 200-day simple moving average is $42.30. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -36.62 and a beta of 0.27.
Insider Activity
In related news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 196,849 shares of company stock valued at $11,344,257 in the last three months. 3.00% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on ELVN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright increased their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Mizuho boosted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Finally, William Blair started coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating for the company. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $75.00.
Read Our Latest Research Report on ELVN
Enliven Therapeutics Company Profile
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Stories
- Five stocks we like better than Enliven Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report).
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
